Trending Now
Exelixis, Inc. (NASDAQ:EXEL) Submits to the FDA Supplemental New Drug Application...
Exelixis, Inc. (NASDAQ:EXEL) has completed the first regulatory submission, a supplemental new drug application (sNDA) for CABOMETYX® (cabozantinib). This incorporates nivolumab (Opdivo) and is...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
How Pot Stocks Shape Up in H2 2020 (TLRY, LHSIF, NUGS,...
The notion that cannabis producers are now moving into ascendency once again in the stock market is not necessarily original as of last month,...
MAKE IT MODERN
LATEST REVIEWS
Cannabis Stocks: Deep Value Opportunity as Legislative Factors Line Up? (CURLF,...
The legislative factor driving the cannabis space in the stock market shouldn’t be underappreciated by long-term investors and speculators alike. The movement...
MAKE IT MODERN
PERFORMANCE TRAINING
The Vaccine Distribution Portfolio (MRNA, XPO, ATVK, FDX)
Every theme can be understood in terms of a basket of stocks with different roles in the ecosystem the makes up the...
Allena Pharmaceuticals Inc (NASDAQ:ALNA) Expands Clinical Trial Sites Of URIROX-2: Initiates Phase 1 Clinical...
Allena Pharmaceuticals Inc (NASDAQ:ALNA) expanded the clinical trial sites of URIROX-2. The company expects to post an interim analysis from this clinical trial in...
ADMA Biologics Inc (NASDAQ: ADMA) Changes the Expiration Date of BIVIGAM and ASCENIV
ADMA Biologics Inc (NASDAQ: ADMA) has announced approval from the U.S Food and Drug Administration (FDA) to change the BIVIGAM and ASCENIV...
NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) To Continue ANA001 Phase 2/3 Clinical Study Without Modification...
NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) has announced the review of safety data by an independent Data Monitoring Committee for 36 patients that were treated...
Telehealth Innovations (VSEE) on day when Dow loses more than 750 points
In the fast-paced world of healthcare technology, VSee Health Inc. (Nasdaq: VSEE) is making headlines with its latest strategic partnership. The San...
MAKE IT MODERN
